Literature DB >> 29436440

Systematic review of the efficacy of statins for the treatment of Alzheimer's disease.

Marta Mejías-Trueba1, María Antonia Pérez-Moreno2, María Ángeles Fernández-Arche3.   

Abstract

Alzheimer's disease (AD) is the most common type of dementia. Recent studies have assessed the possibility of using statins as treatment for AD. However, their efficacy is not clear. In this study, we collected the most relevant information about the efficacy of statins for the treatment of AD. We conducted a systematic literature search using MEDLINE, EMBASE and The Cochrane Library. We included clinical trials, meta-analyses and systematic reviews that analysed the efficacy of statins in AD. We also extracted the characteristics and efficacy results of the studies selected. Of the 304 articles identified, 13 complied with the inclusion criteria. The scientific quality of studies was high and their results indicated that there were no significant differences in the main efficacy variables between statins and placebo treatment for AD. Therefore, according to the available scientific evidence, statins have not shown an improvement in cognition and do not appear to offer significant benefits to patients with AD. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; efficacy; statins; systematic review

Mesh:

Substances:

Year:  2018        PMID: 29436440      PMCID: PMC6330926          DOI: 10.7861/clinmedicine.18-1-54

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  27 in total

1.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.

Authors:  Mikael Simons; Frank Schwärzler; Dieter Lütjohann; Klaus von Bergmann; Konrad Beyreuther; Johannes Dichgans; Henning Wormstall; Tobias Hartmann; Jörg B Schulz
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

Review 2.  Statins and cognition: what can we learn from existing randomized trials?

Authors:  Glen L Xiong; Aaron Benson; P Murali Doraiswamy
Journal:  CNS Spectr       Date:  2005-11       Impact factor: 3.790

3.  Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.

Authors:  Alberto Serrano-Pozo; Gloria L Vega; Dieter Lütjohann; Joseph J Locascio; Marsha K Tennis; Amy Deng; Alireza Atri; Bradley T Hyman; Michael C Irizarry; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

4.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

5.  Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Authors:  H H Feldman; R S Doody; M Kivipelto; D L Sparks; D D Waters; R W Jones; E Schwam; R Schindler; J Hey-Hadavi; D A DeMicco; A Breazna
Journal:  Neurology       Date:  2010-03-03       Impact factor: 9.910

6.  Deprescribing in patients with multimorbidity: a necessary process.

Authors:  Aitana Rodríguez Pérez; Eva Rocío Alfaro Lara; María Dolores Nieto Martín; Alberto Ruiz Cantero; Bernardo Santos Ramos
Journal:  Eur J Intern Med       Date:  2015-07-04       Impact factor: 4.487

7.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Authors:  M Sano; K L Bell; D Galasko; J E Galvin; R G Thomas; C H van Dyck; P S Aisen
Journal:  Neurology       Date:  2011-07-27       Impact factor: 9.910

8.  Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

Authors:  D Larry Sparks; Marwan N Sabbagh; Donald J Connor; Jean Lopez; Lenore J Launer; Suzana Petanceska; Patrick Browne; Dawn Wassar; Sherry Johnson-Traver; Jeff Lochhead; Chuck Ziolkowski
Journal:  Curr Alzheimer Res       Date:  2005-07       Impact factor: 3.498

9.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

10.  Systematic review of atorvastatin for the treatment of Alzheimer's disease.

Authors:  Yuan Sun; Genfa Wang; Zhihong Pan; Shuyan Chen
Journal:  Neural Regen Res       Date:  2012-06-15       Impact factor: 5.135

View more
  8 in total

1.  Identification of Potential Targets Linked to the Cardiovascular/Alzheimer's Axis through Bioinformatics Approaches.

Authors:  Francisco Andújar-Vera; Cristina García-Fontana; Raquel Sanabria-de la Torre; Sheila González-Salvatierra; Luis Martínez-Heredia; Iván Iglesias-Baena; Manuel Muñoz-Torres; Beatriz García-Fontana
Journal:  Biomedicines       Date:  2022-02-06

2.  Effects of different kinds of anti-Alzheimer's disease drugs on cognitive improvement: protocol for a systematic review and network meta-analysis of phase III clinical trials.

Authors:  Diyang Lyu; Min Gong; Yong Zhang; Xuanxin Lyu
Journal:  Syst Rev       Date:  2022-05-03

Review 3.  Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease.

Authors:  Tosha Williams; David R Borchelt; Paramita Chakrabarty
Journal:  Mol Neurodegener       Date:  2020-01-31       Impact factor: 18.879

4.  Depression as a Risk Factor for Dementia and Alzheimer's Disease.

Authors:  Vanesa Cantón-Habas; Manuel Rich-Ruiz; Manuel Romero-Saldaña; Maria Del Pilar Carrera-González
Journal:  Biomedicines       Date:  2020-10-28

Review 5.  Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.

Authors:  Ruth Peters; John Breitner; Sarah James; Gregory A Jicha; Pierre-Francois Meyer; Marcus Richards; A David Smith; Hussein N Yassine; Erin Abner; Atticus H Hainsworth; Patrick G Kehoe; Nigel Beckett; Christopher Weber; Craig Anderson; Kaarin J Anstey; Hiroko H Dodge
Journal:  Alzheimers Dement (N Y)       Date:  2021-12-08

Review 6.  Statins and cognition: Modifying factors and possible underlying mechanisms.

Authors:  Tahereh Jamshidnejad-Tosaramandani; Soheila Kashanian; Mohamed H Al-Sabri; Daniela Kročianová; Laura E Clemensson; Mélissa Gentreau; Helgi B Schiöth
Journal:  Front Aging Neurosci       Date:  2022-08-15       Impact factor: 5.702

Review 7.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

8.  Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.

Authors:  Adrian L Oblak; Peter B Lin; Kevin P Kotredes; Ravi S Pandey; Dylan Garceau; Harriet M Williams; Asli Uyar; Rita O'Rourke; Sarah O'Rourke; Cynthia Ingraham; Daria Bednarczyk; Melisa Belanger; Zackary A Cope; Gabriela J Little; Sean-Paul G Williams; Carl Ash; Adam Bleckert; Tim Ragan; Benjamin A Logsdon; Lara M Mangravite; Stacey J Sukoff Rizzo; Paul R Territo; Gregory W Carter; Gareth R Howell; Michael Sasner; Bruce T Lamb
Journal:  Front Aging Neurosci       Date:  2021-07-23       Impact factor: 5.702

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.